A role for activated Cdc42 in glioblastoma multiforme invasion

Oncotarget

Volumn 7, Issue 35, 2016, Pages 56958-56975

  Okura, Hidehiro ^a,b   Golbourn, Brian J ^a   Shahzad, Uswa ^a   Agnihotri, Sameer ^a   Sabha, Nesrin ^e   Krieger, Jonathan R ^a   Figueiredo, Carlyn A ^a   Chalil, Alan ^a   Landon Brace, Natalie ^a   Riemenschneider, Alexandra ^a   Arai, Hajime ^b   Smith, Christian A ^a   Xu, Songli ^d   Kaluz, Stefan ^d   Marcus, Adam I ^d   Van Meir, Erwin G ^d   Rutka, James T ^a,c  

^a HOSPITAL FOR SICK CHILDREN   (Canada)

^b JUNTENDO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c UNIVERSITY OF TORONTO   (Canada)

^d EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e HOSPITAL FOR SICK CHILDREN RESEARCH INSTITUTE   (Canada)

Author keywords

cdc42; Glioblastoma; Invasion; IQGAP1 and pFAK; Migration

Indexed keywords

FOCAL ADHESION KINASE; IQ MOTIF CONTAINING GUANOSINE TRIPHOSPHATASE ACTIVATING PROTEIN 1; PROTEIN CDC42; DOXYCYCLINE; FOCAL ADHESION KINASE 1; GUANOSINE TRIPHOSPHATASE ACTIVATING PROTEIN; PTK2 PROTEIN, HUMAN; SMALL INTERFERING RNA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BINDING AFFINITY; CELL INVASION; CELL MIGRATION; CELL STRUCTURE; CONTROLLED STUDY; ENZYME LOCALIZATION; FILOPODIUM; FOCAL ADHESION; GLIOBLASTOMA; HUMAN; HUMAN CELL; IMMUNOPRECIPITATION; MASS SPECTROMETRY; MOLECULAR PATHOLOGY; MOUSE; NONHUMAN; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; TUMOR INVASION; WILD TYPE; ANIMAL; BRAIN TUMOR; CANCER TRANSPLANTATION; CELL ADHESION; CELL MOTION; CELL SURVIVAL; CHEMISTRY; DISEASE EXACERBATION; DISEASE FREE SURVIVAL; DOMINANT GENE; GENE EXPRESSION REGULATION; GLIOMA; METABOLISM; PATHOLOGY; PHENOTYPE; PHOSPHORYLATION; PSEUDOPODIUM; TUMOR CELL LINE;

ANIMALS; BRAIN NEOPLASMS; CDC42 GTP-BINDING PROTEIN; CELL ADHESION; CELL LINE, TUMOR; CELL MOVEMENT; CELL SURVIVAL; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; DOXYCYCLINE; FOCAL ADHESION KINASE 1; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, DOMINANT; GLIOBLASTOMA; GLIOMA; HUMANS; MICE; NEOPLASM INVASIVENESS; NEOPLASM TRANSPLANTATION; PHENOTYPE; PHOSPHORYLATION; PSEUDOPODIA; RAS GTPASE-ACTIVATING PROTEINS; RNA, SMALL INTERFERING;

EID: 84984908604     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.10925     Document Type: Article

References (54)

1. Salhia B, Tran NL, Symons M, Winkles JA, Rutka JT and Berens ME. Molecular pathways triggering glioma cell invasion. Expert Rev Mol Diagn. 2006; 6:613-626.
2. Khalil BD and El-Sibai M. Rho GTPases in primary brain tumor malignancy and invasion. J Neurooncol. 2012; 108:333-339.
3. Langlois A, Lee S, Kim DS, Dirks PB and Rutka JT. p16(ink4a) and retinoic acid modulate rhoA and GFAP expression during induction of a stellate phenotype in U343 MG-A astrocytoma cells. Glia. 2002; 40:85-94.
4. Salhia B, Rutten F, Nakada M, Beaudry C, Berens M, Kwan A and Rutka JT. Inhibition of Rho-kinase affects astrocytoma morphology, motility, and invasion through activation of Rac1. Cancer Res. 2005; 65:8792-8800.
5. Weeks A, Okolowsky N, Golbourn B, Ivanchuk S, Smith C and Rutka JT. ECT2 and RASAL2 mediate mesenchymalamoeboid transition in human astrocytoma cells. Am J Pathol. 2012; 181:662-674.
6. Etienne-Manneville S and Hall A. Rho GTPases in cell biology. Nature. 2002; 420:629-635.
7. Sahai E and Marshall CJ. RHO-GTPases and cancer. Nat Rev Cancer. 2002; 2:133-142.
8. Raftopoulou M and Hall A. Cell migration: Rho GTPases lead the way. Dev Biol. 2004; 265:23-32.
9. Hall A. Rho GTPases and the actin cytoskeleton. Science. 1998; 279:509-514.
10. Jaffe AB and Hall A. Rho GTPases: biochemistry and biology. Annu Rev Cell Dev Biol. 2005; 21:247-269.
11. Symons M and Segall JE. Rac and Rho driving tumor invasion: who's at the wheel? Genome Biol. 2009; 10:213.
12. Bustelo XR, Sauzeau V and Berenjeno IM. GTP-binding proteins of the Rho/Rac family: regulation, effectors and functions in vivo. Bioessays. 2007; 29:356-370.
13. Van Aelst L and D'Souza-Schorey C. Rho GTPases and signaling networks. Genes Dev. 1997; 11:2295-2322.
14. Karlsson R, Pedersen ED, Wang Z and Brakebusch C. Rho GTPase function in tumorigenesis. Biochim Biophys Acta. 2009; 1796:91-98.
15. Li H, Peyrollier K, Kilic G and Brakebusch C. Rho GTPases and cancer. Biofactors. 2014; 40:226-235.
16. Salhia B, Hwang JH, Smith CA, Nakada M, Rutka F, Symons M and Rutka JT. Role of myosin II activity and the regulation of myosin light chain phosphorylation in astrocytomas. Cell Motil Cytoskeleton. 2008; 65:12-24.
17. DeMali KA and Burridge K. Coupling membrane protrusion and cell adhesion. J Cell Sci. 2003; 116:2389-2397.
18. Huveneers S and Danen EH. Adhesion signaling-crosstalk between integrins, Src and Rho. J Cell Sci. 2009; 122:1059-1069.
19. Krukonis ES, Dersch P, Eble JA and Isberg RR. Differential effects of integrin alpha chain mutations on invasin and natural ligand interaction. J Biol Chem. 1998; 273:31837-31843.
20. Parsons JT, Martin KH, Slack JK, Taylor JM and Weed SA. Focal adhesion kinase: a regulator of focal adhesion dynamics and cell movement. Oncogene. 2000; 19:5606-5613.
21. Schlaepfer DD, Hauck CR and Sieg DJ. Signaling through focal adhesion kinase. Progress in biophysics and molecular biology. 1999; 71:435-478.
22. Natarajan M, Hecker TP and Gladson CL. FAK signaling in anaplastic astrocytoma and glioblastoma tumors. Cancer journal. 2003; 9:126-133.
23. Hecker TP, Grammer JR, Gillespie GY, Stewart J, Jr. and Gladson CL. Focal adhesion kinase enhances signaling through the Shc/extracellular signal-regulated kinase pathway in anaplastic astrocytoma tumor biopsy samples. Cancer Res. 2002; 62:2699-2707.
24. Rutka JT, Muller M, Hubbard SL, Forsdike J, Dirks PB, Jung S, Tsugu A, Ivanchuk S, Costello P, Mondal S, Ackerley C and Becker LE. Astrocytoma adhesion to extracellular matrix: functional significance of integrin and focal adhesion kinase expression. Journal of neuropathology and experimental neurology. 1999; 58:198-209.
25. Wang D, Grammer JR, Cobbs CS, Stewart JE, Jr., Liu Z, Rhoden R, Hecker TP, Ding Q and Gladson CL. p125 focal adhesion kinase promotes malignant astrocytoma cell proliferation in vivo. J Cell Sci. 2000; 113 Pt 23:4221-4230.
26. Zagzag D, Friedlander DR, Margolis B, Grumet M, Semenza GL, Zhong H, Simons JW, Holash J, Wiegand SJ and Yancopoulos GD. Molecular events implicated in brain tumor angiogenesis and invasion. Pediatric neurosurgery. 2000; 33:49-55.
27. Olson MF, Ashworth A and Hall A. An essential role for Rho, Rac, and Cdc42 GTPases in cell cycle progression through G1. Science. 1995; 269:1270-1272.
28. Lee S, Craig BT, Romain CV, Qiao J and Chung DH. Silencing of CDC42 inhibits neuroblastoma cell proliferation and transformation. Cancer Lett. 2014; 355:210-216.
29. Gao CF, Xie Q, Su YL, Koeman J, Khoo SK, Gustafson M, Knudsen BS, Hay R, Shinomiya N and Vande Woude GF. Proliferation and invasion: plasticity in tumor cells. Proc Natl Acad Sci U S A. 2005; 102:10528-10533.
30. Xie Q, Mittal S and Berens ME. Targeting adaptive glioblastoma: an overview of proliferation and invasion. Neuro Oncol. 2014; 16:1575-1584.
31. Le Clainche C, Schlaepfer D, Ferrari A, Klingauf M, Grohmanova K, Veligodskiy A, Didry D, Le D, Egile C, Carlier MF and Kroschewski R. IQGAP1 stimulates actin assembly through the N-WASP-Arp2/3 pathway. J Biol Chem. 2007; 282:426-435.
32. Nabeshima K, Shimao Y, Inoue T and Koono M. Immunohistochemical analysis of IQGAP1 expression in human colorectal carcinomas: its overexpression in carcinomas and association with invasion fronts. Cancer Lett. 2002; 176:101-109.
33. McDonald KL, O'Sullivan MG, Parkinson JF, Shaw JM, Payne CA, Brewer JM, Young L, Reader DJ, Wheeler HT, Cook RJ, Biggs MT, Little NS, Teo C, Stone G and Robinson BG. IQGAP1 and IGFBP2: valuable biomarkers for determining prognosis in glioma patients. Journal of neuropathology and experimental neurology. 2007; 66:405-417.
34. Balenci L, Clarke ID, Dirks PB, Assard N, Ducray F, Jouvet A, Belin MF, Honnorat J and Baudier J. IQGAP1 protein specifies amplifying cancer cells in glioblastoma multiforme. Cancer Res. 2006; 66:9074-9082.
35. Hu B, Shi B, Jarzynka MJ, Yiin JJ, D'Souza-Schorey C and Cheng SY. ADP-ribosylation factor 6 regulates glioma cell invasion through the IQ-domain GTPase-activating protein 1-Rac1-mediated pathway. Cancer Res. 2009; 69:794-801.
36. Choi S, Thapa N, Hedman AC, Li Z, Sacks DB and Anderson RA. IQGAP1 is a novel phosphatidylinositol 4,5 bisphosphate effector in regulation of directional cell migration. The EMBO journal. 2013; 32:2617-2630.
37. Briggs MW and Sacks DB. IQGAP proteins are integral components of cytoskeletal regulation. EMBO reports. 2003; 4:571-574.
38. Demuth T and Berens ME. Molecular mechanisms of glioma cell migration and invasion. J Neurooncol. 2004; 70:217-228.
39. Nakada M, Drake KL, Nakada S, Niska JA and Berens ME. Ephrin-B3 ligand promotes glioma invasion through activation of Rac1. Cancer Res. 2006; 66:8492-8500.
40. Jarzynka MJ, Hu B, Hui KM, Bar-Joseph I, Gu W, Hirose T, Haney LB, Ravichandran KS, Nishikawa R and Cheng SY. ELMO1 and Dock180, a bipartite Rac1 guanine nucleotide exchange factor, promote human glioma cell invasion. Cancer Res. 2007; 67:7203-7211.
41. Salhia B, Tran NL, Chan A, Wolf A, Nakada M, Rutka F, Ennis M, McDonough WS, Berens ME, Symons M and Rutka JT. The guanine nucleotide exchange factors trio, Ect2, and Vav3 mediate the invasive behavior of glioblastoma. Am J Pathol. 2008; 173:1828-1838.
42. Thompson G, Owen D, Chalk PA and Lowe PN. Delineation of the Cdc42/Rac-binding domain of p21-activated kinase. Biochemistry. 1998; 37:7885-7891.
43. Rohatgi R, Ma L, Miki H, Lopez M, Kirchhausen T, Takenawa T and Kirschner MW. The interaction between N-WASP and the Arp2/3 complex links Cdc42-dependent signals to actin assembly. Cell. 1999; 97:221-231.
44. Hong L, Kenney SR, Phillips GK, Simpson D, Schroeder CE, Noth J, Romero E, Swanson S, Waller A, Strouse JJ, Carter M, Chigaev A, Ursu O, Oprea T, Hjelle B, Golden JE, et al. Characterization of a Cdc42 protein inhibitor and its use as a molecular probe. J Biol Chem. 2013; 288:8531-8543.
45. Chen HY, Yang YM, Stevens BM and Noble M. Inhibition of redox/Fyn/c-Cbl pathway function by Cdc42 controls tumour initiation capacity and tamoxifen sensitivity in basal-like breast cancer cells. EMBO Mol Med. 2013; 5:723-736.
46. Zins K, Lucas T, Reichl P, Abraham D and Aharinejad S. A Rac1/Cdc42 GTPase-specific small molecule inhibitor suppresses growth of primary human prostate cancer xenografts and prolongs survival in mice. PLoS One. 2013; 8:e74924.
47. Sakamori R, Yu S, Zhang X, Hoffman A, Sun J, Das S, Vedula P, Li G, Fu J, Walker F, Yang CS, Yi Z, Hsu W, Yu DH, Shen L, Rodriguez AJ, et al. CDC42 inhibition suppresses progression of incipient intestinal tumors. Cancer Res. 2014; 74:5480-5492.
48. Arias-Romero LE and ChernoffJ. Targeting Cdc42 in cancer. Expert opinion on therapeutic targets. 2013; 17:1263-1273.
49. Fortin SP, Ennis MJ, Schumacher CA, Zylstra-Diegel CR, Williams BO, Ross JT, Winkles JA, Loftus JC, Symons MH and Tran NL. Cdc42 and the guanine nucleotide exchange factors Ect2 and trio mediate Fn14-induced migration and invasion of glioblastoma cells. Mol Cancer Res. 2012; 10:958-968.
50. Gossen M, Freundlieb S, Bender G, Muller G, Hillen W and Bujard H. Transcriptional activation by tetracyclines in mammalian cells. Science. 1995; 268:1766-1769.
51. Kaur B, Brat DJ, Devi NS and Van Meir EG. Vasculostatin, a proteolytic fragment of brain angiogenesis inhibitor 1, is an antiangiogenic and antitumorigenic factor. Oncogene. 2005; 24:3632-3642.
52. Berens ME and Beaudry C. Radial monolayer cell migration assay. Methods Mol Med. 2004; 88:219-224.
53. Valster A, Tran NL, Nakada M, Berens ME, Chan AY and Symons M. Cell migration and invasion assays. Methods. 2005; 37:208-215.
54. Verhaak RG, Hoadley KA, Purdom E, Wang V, Qi Y, Wilkerson MD, Miller CR, Ding L, Golub T, Mesirov JP, Alexe G, Lawrence M, O'Kelly M, Tamayo P, Weir BA, Gabriel S, et al. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell. 2010; 17:98-110.